Astellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Above 50 Day Moving Average – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $14.06 and traded as high as $15.17. Astellas Pharma shares last traded at $15.05, with a volume of 76,049 shares.

Analyst Ratings Changes

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The firm has a market cap of $27.24 billion, a PE ratio of 11.45 and a beta of 0.08. The company has a current ratio of 1.20, a quick ratio of 0.90 and a debt-to-equity ratio of 0.16. The firm’s 50 day simple moving average is $14.06 and its 200 day simple moving average is $14.63.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).